Literature DB >> 6129413

Autologous bone marrow rescue is unnecessary after very-high-dose cyclophosphamide.

I E Smith, B D Evans, S J Harland, J L Millar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6129413     DOI： 10.1016/s0140-6736(83)91617-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation.

Authors:  C Twelves; R Souhami; P Harper; A Goldstone
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.

Authors:  I E Smith; B D Evans; S J Harland; B A Robinson; J R Yarnold; J G Glees; H T Ford
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Resistance of human T-CFUcs to activated cyclophosphamide: a feature common with critical marrow stem cells?

Authors:  J E Byfield; P M Calabro-Jones
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

4.  Prediction of tumour sensitivity to 4-hydroperoxycyclophosphamide by a glutathione-targeted assay.

Authors:  F Y Lee; D J Flannery; D W Siemann
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.